Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 16/20 | 0.47 |
| ▸ | ABL1 | P00519 | 10/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 4/20 | 0.47 |
| ▸ | RIPK2 | O43353 | 4/20 | 0.47 |
| ▸ | FYN | P06241 | 4/20 | 0.47 |
| ▸ | EGFR | P00533 | 3/20 | 0.47 |
| ▸ | KDR | P35968 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | PRKACA | P17612 | 3/20 | 0.47 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.47 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.47 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.47 |
| ▸ | CSK | P41240 | 3/20 | 0.47 |
| ▸ | PRKD2 | Q9BZL6 | 3/20 | 0.47 |
| ▸ | LCK | P06239 | 2/20 | 0.47 |
| ▸ | YES1 | P07947 | 2/20 | 0.47 |
| ▸ | LYN | P07948 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15929311 | 0.84 | SRC (0.61) | SRCABL1KDM4EALDH1A1HTT | |
| SCHEMBL22388667 | 0.82 | SRC (0.40) | SRCABL1KDM4EALDH1A1HTT | |
| SCHEMBL10457496 | 0.82 | SRC (0.42) | SRCABL1KDM4EALDH1A1HTT | |
| SCHEMBL10261882 | 0.82 | SRC (0.41) | SRCABL1KDM4EALDH1A1HTT | |
| SCHEMBL15101790 | 0.82 | SRC (0.40) | SRCABL1KDM4EALDH1A1HTT | |
| SCHEMBL19303475 | 0.79 | PIK3CD (0.36) | SRCABL1KDM4EALDH1A1HTT | |
| SCHEMBL22002210 | 0.75 | SRC (0.35) | SRCABL1KDM4EALDH1A1HTT | |
| SCHEMBL14584045 | 0.71 | SRC (0.33) | SRCABL1KDM4EALDH1A1HTT | |
| SCHEMBL4928772 | 0.71 | KDM4E (0.44) | SRCABL1KDM4EALDH1A1HTT | |
| SCHEMBL4923676 | 0.71 | SRC (0.44) | SRCABL1KDM4EALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240065971-A1 | METHODS OF TREATING ABC-DLBCL USING INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2024-02-29 | — | — | US | disclosed |
| US-20230248730-A1 | USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | PHARMACYCLICS LLC (US) | 2023-08-10 | — | — | US | disclosed |
| US-11672803-B2 | Use of inhibitors of Brutons tyrosine kinase (Btk) | PHARMACYCLICS LLC (US) | 2023-06-13 | — | — | US | disclosed |
| US-20210361657-A1 | USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | PHARMACYCLICS LLC (US) | 2021-11-25 | — | — | US | disclosed |
| US-20180193345-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | PHARMACYCLICS LLC | 2018-07-12 | — | — | US | disclosed |
| US-10016435-B2 | Use of inhibitors of Bruton's tyrosine kinase (Btk) | PHARMACYCLICS LLC (US) | 2018-07-10 | — | — | US | disclosed |
| US-10016435-B2 | Use of inhibitors of Bruton's tyrosine kinase (Btk) | PHARMACYCLICS LLC (US) | 2018-07-10 | — | — | US | disclosed |
| US-10004745-B2 | Use of inhibitors of Bruton'S tyrosine kinase (Btk) | PHARMACYCLICS LLC (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180036313-A1 | USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) | PHARMACYCLICS, INC. | 2018-02-08 | — | — | US | disclosed |
| US-20180036313-A1 | USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) | PHARMACYCLICS, INC. | 2018-02-08 | — | — | US | disclosed |
| US-20120178753-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120165328-A1 | INHIBITORS OF B LYMPHOCYTE KINASE | PHARMACYCLICS, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120100138-A1 | THE USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) | PHARMACYCLICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120101113-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120101114-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120087915-A1 | USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) | PHARMACYCLICS, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-20120071497-A1 | METHODS OF TREATING ABC-DLBCL USING INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120065201-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20110224235-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | PHARMACYCLICS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20100254905-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (18 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178753-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | SRC 17/4885ABL1 1/4885KDM4E 902/4885 |
| US-20120165328-A1 | INHIBITORS OF B LYMPHOCYTE KINASE | BLK, DCK, LTK | SRC 287/4885ABL1 60/4885KDM4E 697/4885 |
| US-10016435-B2 | Use of inhibitors of Bruton's tyrosine kinase (Btk) | BTK, SYK, LYN | SRC 17/4885ABL1 8/4885KDM4E 2459/4885 |
| US-20180036313-A1 | USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) | BTK, SYK, LYN | SRC 17/4885ABL1 8/4885KDM4E 2459/4885 |
| US-20210361657-A1 | USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | BTK, LYN, SYK | SRC 11/4885ABL1 4/4885KDM4E 1786/4885 |
| US-20180193345-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | BTK, ABL1, LYN | SRC 6/4885ABL1 2/4885KDM4E 725/4885 |
| US-20120071497-A1 | METHODS OF TREATING ABC-DLBCL USING INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, BCL6, BCL6B | SRC 33/4885ABL1 19/4885KDM4E 1288/4885 |
| US-20240065971-A1 | METHODS OF TREATING ABC-DLBCL USING INHIBITORS OF BRUTONS TYROSINE KINASE | BTK, BCL6, BCL6B | SRC 42/4885ABL1 27/4885KDM4E 1341/4885 |
| US-10004745-B2 | Use of inhibitors of Bruton'S tyrosine kinase (Btk) | BTK, SYK, LYN | SRC 17/4885ABL1 8/4885KDM4E 2459/4885 |
| US-20120101114-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | SRC 17/4885ABL1 1/4885KDM4E 902/4885 |
| US-20100254905-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | SRC 17/4885ABL1 1/4885KDM4E 902/4885 |
| US-20230248730-A1 | USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | BTK, LYN, SYK | SRC 21/4885ABL1 9/4885KDM4E 2333/4885 |
| US-11672803-B2 | Use of inhibitors of Brutons tyrosine kinase (Btk) | BTK, LYN, SYK | SRC 21/4885ABL1 9/4885KDM4E 2333/4885 |
| US-20120101113-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | SRC 17/4885ABL1 1/4885KDM4E 902/4885 |
| US-20110224235-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | BTK, ABL1, LYN | SRC 6/4885ABL1 2/4885KDM4E 725/4885 |
| US-20120087915-A1 | USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) | BTK, SYK, LYN | SRC 17/4885ABL1 8/4885KDM4E 2459/4885 |
| US-20120065201-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | SRC 17/4885ABL1 1/4885KDM4E 902/4885 |
| US-20120100138-A1 | THE USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) | BTK, SYK, LYN | SRC 20/4885ABL1 13/4885KDM4E 2440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.